[Insert Table 3]
Among COVID-19 patients with hypertension, 169 in 871 patients exposed
to ACEIs/ARBs, and 430 in 2,041 unexposed to ACEIs/ARBs died with
COVID-19. Whereas, 95 in 433 patients exposed to ACEIs/ARBs, and 274 in
1,428 unexposed to ACEIs/ARBs developed a severe/critical COVID-19
disease. The estimated pooled relative risk of mortality and pooled
relative risk of disease severity was 0.73 (95% CI: 0.63-0.86) and 0.72
(95% CI: 0.46-1.12), respectively (Table 2 & Table 3 ). The
overall absolute risk reduction of mortality associated with ACEI/ARB
among COVID-19 patients was 6.7%. The ‘numbers needed to treat to
benefit’ was 15, suggesting that every 15 patients exposed to ACIEs/ARBs
may prevent an additional death.